



Financial Tear Sheet

Corporate Profile

Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

Primary IR Contact

Kristin Hodous

Blueprint Medicines

Phone: 617-714-6674

E-mail:

khodous@blueprintmedicines.com

Stock Information

BPMC (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price **\$85.55**

Change (%) ▼ **0.8 (0.93%)**

Volume 79,377

52 Week Low \$32.43

Market Cap \$3,773,843,077

Rolling EPS -3.89

PE Ratio 0

Shares Outstanding 43,704,031

Data as of February 23, 2018 12:54 p.m. ET



Recent Press Releases & Upcoming Events

February 21, 2018

There are currently no events scheduled.

[Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results](#)

February 14, 2018

[Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018](#)

December 15, 2017

[Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock](#)

SEC Filings

Filing Date

Form

February 21, 2018

10-K

February 21, 2018

S-8

February 21, 2018

8-K

February 20, 2018

4

Corporate Governance

[Jeffrey Albers](#)

Chief Executive Officer

[Marion. Dorsch, Ph.D](#)

Chief Scientific Officer

[Anthony Boral,](#)

Chief Medical

M.D-Ph.D.

Officer

Kate Haviland

Chief Business
Officer

Christoph Lengauer,
Ph.D.

Executive Vice
President

Data provided by Nasdaq. Minimum 15 minutes delayed.